{"id":15862,"date":"2012-11-23T02:30:00","date_gmt":"2012-11-23T01:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/resta-la-prescrizione-con-principio-attivo\/"},"modified":"2012-11-23T02:30:00","modified_gmt":"2012-11-23T01:30:00","slug":"resta-la-prescrizione-con-principio-attivo","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/resta-la-prescrizione-con-principio-attivo\/","title":{"rendered":"The prescription with active ingredient remains"},"content":{"rendered":"

Cursi, but the role of the pharmaceutical company is recognized<\/span><\/i><\/b><\/p>\n

An agreement was found in the Senate Industry Commission on the prescription of drugs, as envisaged by the Development Decree. The obligation of the active ingredient on the recipe remains, but also the possibility of indicating a precise brand next to it. There will therefore be no room for amendments aimed at eliminating the obligation of the active principle. "I am satisfied - Cesare Cursi, president of the Commission, told Pharmakronos - because alongside the possibility of promoting generics there is also the recognition of the role of the pharmaceutical company, because the need to indicate the brand is reconciled". In fact, the text provides that the doctor, when prescribing a new therapy, writes the name of the active ingredient or a specific medicine based on the same active ingredient accompanied by the name of the latter in the recipe.<\/p>\n

<\/font><\/span><\/p>\n

The pharmacist will not be able to replace the designer drug if the non-substitutability clause is affixed to the prescription and when the drug has a price equal to the reimbursement price "unless otherwise requested by the customer".<\/p>\n

<\/font><\/span><\/p>\n

Raffaella Ammirati \u2013 23 November 2012 \u2013 PharmaKronos<\/p>\n

<\/span><\/i><\/p>\n

 <\/p>\n

\u201cGeneric or what is written here?\u201d<\/span><\/a><\/p>\n

<\/span><\/b><\/p>\n

By James Giannecchini<\/span><\/a> on 23 November 2012 Those who the magazine pharmacy<\/p>\n

<\/span><\/i><\/p>\n

To the Senate of the Republic<\/span><\/a>, there seems to be finally an agreement between Sv<\/p>","protected":false},"excerpt":{"rendered":"

Cursi, ma si riconosce il ruolo dell’azienda farmaceutica Si è trovato un accordo, in Commissione Industria del Senato sulla prescrizione dei farmaci, come prevista dal Dl Sviluppo. Resta l’obbligo del principio attivo sulla ricetta, ma anche la possibilità di indicare accanto una marca precisa. Non ci sarà spazio, dunque, per emendamenti mirati eliminare l’obbligo del …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15862","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15862"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15862\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}